Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
12 articles
Newest firstBackground In recent decades, the potency of cannabis resin increased globally, raising concerns, as higher potency has been associated with increased risk of psychiatric harms at the individual level. The aim here was to examine whether changes over time in the potency of seized cannabis resin samples were associated with psychiatric harms at the population level. Methods Data on ∆-9-tetrahydrocannabinol (THC) co…
Open article record in new tab ↗PURPOSE OF REVIEW: This review evaluates structural neuroimaging research on substance-related psychosis to determine if these conditions share common neurobiological pathways with primary psychotic disorders, such as schizophrenia, or exhibit unique signatures. RECENT FINDINGS: Research indicates that methamphetamine, cannabis, and cocaine induce significant structural changes, including cortical thinning and gre…
Open article record in new tab ↗Recreational use of psychotogenic drugs has become more common in the last 30 years with consequent increase in drug-induced psychosis; 25-50% of such psychoses progress to schizophrenia within 5 years. Most cases result from abuse of methamphetamine or cannabis. The spread of methamphetamine psychosis has occurred without any liberalisation of laws; it is highly addictive and easy to make in small "kitchen" labs.…
Open article record in new tab ↗Background Cannabis use is linked to treatment non-adherence and relapses in psychotic disorders. Antipsychotic medication is effective for relapse prevention in primary psychoses, but its effectiveness after cannabis-induced psychosis (CIP) remains unclear. Aims To examine the effectiveness of antipsychotic medication for relapse prevention following the first clinically diagnosed CIP. Method A cohort of 1772 pat…
This multisite, prospective randomized controlled trial examined transition rates to schizophrenia in individuals with recent-onset substance-induced psychotic disorder (SIPD) or brief psychotic disorder (BPD), and evaluated the efficacy of a specialized early intervention (SEI) designed to reduce this transition. We enrolled 1,000 participants (aged 16-40 years) across five Egyptian centers, randomly allocating t…
Background Substance use may be associated with the onset of psychotic symptoms, necessitating treatment for individuals with comorbid mental health and substance use disorders (MHD/SUD). COVID-19 significantly impacted individuals with MHD/SUD, reducing access to appropriate care and treatment. Changes in drug availability and prices during the pandemic may have influenced drug consumption. This study aimed to de…
Open article record in new tab ↗It is a paradox that psychotomimetic drugs can relieve symptoms that increase risk of and cooccur with psychosis, such as attention and motivational deficits (e.g., amphetamines), pain (e.g., cannabis) and symptoms of depression (e.g., psychedelics, dissociatives). We introduce the ideas of psychotomimetic compensation and psychotomimetic sensitization to explain this paradox. Psychotomimetic compensation refers t…
Open article record in new tab ↗Background and aims High-potency cannabis has been associated with increased risk of psychosis, but a lack of prospective data hinders understanding of causality in this relationship. This study aimed to combine prospective report of cannabis use with retrospective report of potency to infer the potency of cannabis used in adolescence and explore whether use of cannabis, and the use of high-potency cannabis, in ad…
Open article record in new tab ↗Background Current treatment of cannabis-induced psychosis (CIP) focus on the presenting symptoms of individual patient. Therefore, the objective of this study was to investigate the efficacy of pharmacological treatment for CIP in a retrospective manner. Methods A retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. Patients aged mor…
Background Approximately 188 million people use cannabis yearly worldwide, and it has recently been legalised in 11 US states, Canada, and Uruguay for recreational use. The potential for increased cannabis use highlights the need to better understand its risks, including the acute induction of psychotic and other psychiatric symptoms. We aimed to investigate the effect of the cannabis constituent Δ9-tetrahydrocann…
Background Changes in cannabis regulation globally make it increasingly important to determine what predicts an individual's risk of experiencing adverse drug effects. Relevant studies have used diverse self-report measures of cannabis use, and few include multiple biological measures. Here we aimed to determine which biological and self-report measures of cannabis use predict cannabis dependency and acute psychot…
The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This study aimed to determine the effects of THC and CBD, both alone and in combination on psychotic symptoms and memory function. A randomised, double-blind crossover design compared the…